JAMA Network
About The Study: This randomized clinical trial found that continuing glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonist in the preprocedural period increased clinically significant residual gastric volume (RGV) but did not increase the risk of other adverse events. Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
